Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?

Dahl NV, Henry DH, Coyne DW.

Semin Dial. 2008 May-Jun;21(3):210-1. doi: 10.1111/j.1525-139X.2008.00435.x. Epub 2008 Apr 6.

PMID:
18397204
2.

It's time to compare anemia management strategies in hemodialysis.

Coyne DW.

Clin J Am Soc Nephrol. 2010 Apr;5(4):740-2. doi: 10.2215/CJN.02490409. Epub 2010 Mar 18.

3.

Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?

Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR.

Adv Chronic Kidney Dis. 2009 Mar;16(2):143-51. doi: 10.1053/j.ackd.2008.12.008. Review.

PMID:
19233073
5.

Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome.

Besarab A, Hörl WH, Silverberg D.

Oncologist. 2009;14 Suppl 1:22-33. doi: 10.1634/theoncologist.2009-S1-22. Review.

6.

The anemia of heart failure.

Silverberg DS, Wexler D, Palazzuoli A, Iaina A, Schwartz D.

Acta Haematol. 2009;122(2-3):109-19. doi: 10.1159/000243795. Epub 2009 Nov 10.

PMID:
19907148
7.

Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated.

Katodritou E, Zervas K, Terpos E, Brugnara C.

Br J Haematol. 2008 Jul;142(1):3-10. doi: 10.1111/j.1365-2141.2008.07163.x. Epub 2008 Apr 22. Review.

PMID:
18430192
8.

Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.

Singh A.

Semin Dial. 2009 Jan-Feb;22(1):64-9. doi: 10.1111/j.1525-139X.2008.00518.x. Epub 2008 Dec 5. Review.

PMID:
19175537
10.
11.

IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency.

Won HS, Kim HG, Yun YS, Jeon EK, Ko YH, Kim YS, Kim YO, Yoon SA.

Hemodial Int. 2012 Jan;16(1):31-7. doi: 10.1111/j.1542-4758.2011.00635.x.

PMID:
22284696
12.

Malarial anemia leads to adequately increased erythropoiesis in asymptomatic Kenyan children.

Verhoef H, West CE, Kraaijenhagen R, Nzyuko SM, King R, Mbandi MM, van Laatum S, Hogervorst R, Schep C, Kok FJ.

Blood. 2002 Nov 15;100(10):3489-94. Epub 2002 Jul 25.

13.

A comprehensive vision for intravenous iron therapy.

Coyne DW.

Am J Kidney Dis. 2008 Dec;52(6 Suppl):S14-20. doi: 10.1053/j.ajkd.2008.09.003.

PMID:
19010257
14.

Optimizing anemia management in hospitalized patients with end-stage renal disease.

Heung M, Mueller BA, Segal JH.

Ann Pharmacother. 2009 Feb;43(2):276-82. doi: 10.1345/aph.1L195. Epub 2009 Jan 13. Review.

PMID:
19141655
16.

Dialysis adequacy and response to erythropoiesis-stimulating agents: what is the evidence base?

Locatelli F, Del Vecchio L, Pozzoni P, Andrulli S.

Semin Nephrol. 2006 Jul;26(4):269-74. Review.

PMID:
16949464
17.

[Major thrombocytosis associated with severe anemia in children. Diagnosis of 9 cases].

Diagne I, Sall MG, Camara B, Ndiaye O, Sarr M, Ba M, Sow HD, Kuakuvi N.

Dakar Med. 2002;47(1):52-6. French.

PMID:
15776594
18.

Update on erythropoiesis-stimulating agents and clinical trials in oncology.

Aapro M, Spivak JL.

Oncologist. 2009;14 Suppl 1:6-15. doi: 10.1634/theoncologist.2009-S1-6. Review.

19.

Iron deficiency anemia with marked thrombocytosis complicated by central retinal vein occlusion.

Nagai T, Komatsu N, Sakata Y, Miura Y, Ozawa K.

Intern Med. 2005 Oct;44(10):1090-2.

20.

Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.

Juneja V, Keegan P, Gootenberg JE, Rothmann MD, Shen YL, Lee KY, Weiss KD, Pazdur R.

Clin Cancer Res. 2008 Jun 1;14(11):3242-7. doi: 10.1158/1078-0432.CCR-07-1872.

Supplemental Content

Support Center